Analysts: Stryker’s portfolio, robot will drive market gains

Stryker is positioned for success in robot sales and market gains, thanks to its robust portfolio and in-demand robotic surgery platform, according to an analysis by Zacks Equity Research.

Advertisement

Five takeaways:

1. Stryker has recently seen a “significant rise” in new installations of its Mako Total Knee platform.

2. The company anticipates solid robot sales in 2019 at hospitals, as well as heightened surgeon interest in orthopedic robotic programs.

3. Stryker management is hopeful about gaining regulatory approvals for the company’s total knee products in China and Japan this year.

4. The wide range of products in Stryker’s portfolio is expected to shield the company from any significant sales shortfall during economic downturns.

5. Stryker’s long-term earnings growth rate is promising, at 10 percent.

More articles on devices:
Centinel Spine device for total disc replacement celebrates 18 years
10 device company notes
Stryker enters into licensing, distribution agreement with Conformis

At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.

Register to Attend Webinar

160 ambulatory leaders just ranked the EHR as the single system most overdue for AI reinvention

Tuesday, August 11
12:00 PM - 1:00 PM CDT

Presenter: Gautam Shah, MBA, FACHDM, NextGen Healthcare

Advertisement

Next Up in Spinal Tech

Advertisement

Comments are closed.